Summary of Purpose
To evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke.Read More →
The following dates are available for this trial. Trial information last updated on 10 December 2001.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- CIBA-GEIGY Corporation
Randomized, double-blind, placebo-controlled, ascending-dose phase IIa trial of 32 patients at 7 centers.